Armata Pharmaceuticals, Inc. (ARMP) Misses Q4 EPS by 323c

Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q4 EPS of ($3.42), $3.23 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.48 million.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.

You May Also Be Interested In

• Bessent: U.S. will enforce 'zero leakage' approach to Iran sanctions
• Macquarie Reiterates Outperform Rating on XPeng (XPEV)
• Nutex Health reports unauthorized access to company network data